BioCentury | Dec 31, 2020
Distillery Therapeutics

Protease inhibitor SERPINB9 as a melanoma, breast cancer target

DISEASE CATEGORY: Cancer INDICATION: Melanoma; breast cancer Inhibiting SERPINB9, a serine protease inhibitor, could treat melanoma and breast cancer. In a melanoma mouse model, tumor-specific SERPINB9 knockout reduced tumor size and the number of melanoma...
BioCentury | Nov 11, 2020
Product Development

In vivo gene editing advances with Intellia’s trial start, grant

Intellia took CRISPR-based in vivo gene editing two steps forward this week with the start of the first clinical trial of a systemically delivered therapy and the announcement that the biotech was...
BioCentury | May 23, 2020
Emerging Company Profile

Praxis: connecting the neurological dots

Praxis’ neurology pipeline emerged from genetic data that found neuronal imbalances to be at the root of several disorders that were previously thought to be unrelated. The company debuted this month with $100 million in...
BioCentury | Dec 3, 2019
Company News

Xenon licenses sodium channel inhibitors to Neurocrine to fund more advanced epilepsy programs

Xenon has exclusively licensed its sodium channel inhibitors for epilepsy to Neurocrine to focus on advancing its potassium channel modulators through the clinic. The deal adds a new indication to Neurocrine's neurology portfolio and gives...
BioCentury | Oct 30, 2019
Financial News

Pfizer surprises Street with Vyndaqel sales, uptake

Uptake of Pfizer's Vyndaqel tafamidis in 3Q19 surpassed a consensus estimate following its approval in May, adding to expectations for a drug the pharma has already touted as a potential blockbuster to treat transthyretin-mediated amyloid...
BioCentury | Oct 3, 2019

SERPINB1 and CXCR6 inhibition for multiple sclerosis

DISEASE CATEGORY: Autoimmune disease INDICATION: Multiple sclerosis (MS) Blocking the leukocyte esterase inhibitor SERPINB1 or the chemokine receptor CXCR6 could help treat MS. In the experimental autoimmune encephalomyelitis (EAE) mouse model of MS, systemic knockout...
BioCentury | Aug 1, 2019
Company News

Vertex’s CF ‘firepower’ to fund more deals, broader pipeline

Vertex unveiled a series of new programs Wednesday and provided a glimpse of how it plans to use the cash from its cystic fibrosis portfolio to fuel deals that will continue to propel the company...
BioCentury | Jun 7, 2019
Product Development

How early biomarkers and constant iteration fuel Vertex’s R&D efficiency

As Vertex prepares its fourth NDA for a cystic fibrosis drug in six years, EVP of Global Research and CSO David Altshuler credits the biotech’s R&D efficiency to a focus on agents that show more...
BioCentury | Mar 28, 2019

Polyneuron’s surgical strike

Polyneuron’s broad platform and method of directly targeting autoantibodies rather than B cells for autoimmune diseases prompted Sofinnova Partners and New Enterprise Associates to invest in the Basel-based company’s CHF22.5 million ($22.6 million) series A...
BioCentury | Mar 28, 2019
Financial News

Polyneuron raises $22.6M series A to bring neuropathy therapy into clinic

Backed by Sofinnova Partners and New Enterprise Associates, Polyneuron raised CHF22.5M ($22.6 million) in a series A round to bring its anti-MAG neuropathy therapy, PN-1007, into the clinic. Polyneuron Pharmaceuticals AG (Basel, Switzerland) is developing...
Items per page:
1 - 10 of 204